$10.5 Billion Neurostimulation Devices Market Assessment 2020-2026 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jul 6, 2020--
The “Global Neurostimulation Devices Market By Devices, By Applications, By Region, Industry Analysis and Forecast, 2020 - 2026” report has been added to ResearchAndMarkets.com’s offering.
The Global Neurostimulation Devices Market size is expected to reach $10.5 billion by 2026, rising at a market growth of 12.5% CAGR during the forecast period.
Among the many treatment options for overactive bladder symptoms is sacral nerve stimulation therapy (also known as sacral neuromodulation therapy). The treatment of overactive bladder with or without urine leakage and bladder vacuum can be done with sacral nerve stimulation therapy.
In certain individuals who have not undergone more conservative treatments including drug therapy, the sacral nerve stimulation therapy is more suitable. Usually, a medication, behavioral therapy, and/or physical therapy must be completed before the sacral nerve stimulation therapy is taken into consideration.
Stimulation of the vagus nerve reduces seizures by transmitting normal, mild electrical energy through the vagus nerve into the brain. Often it is recognized as a “brain pacemaker.” A pacemaker is inserted into the chest under the skin. The vagus nerve of the neck is wound around a cable from the device.
The major strategies followed by the market participants are Partnerships. Based on the Analysis presented in the Cardinal matrix, Abbott Laboratories, Medtronic PLC, and Boston Scientific Corporation are the forerunners in the Neurostimulation Devices Market. Companies such as LivaNova PLC, NeuroPace, Inc., Nevro Corporation, NeuroSigma, Inc., Neuronetics, Inc., Synapse Biomedical, Inc., and Integer Holdings Corporation are some of the key innovators in the market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Nevro Corporation, Medtronic PLC, NeuroSigma, Inc., Integer Holdings Corporation, LivaNova PLC, NeuroPace, Inc., Neuronetics, Inc., and Synapse BioMedical, Inc.
Recent Strategies Deployed
Partnerships, Collaborations, and Agreements
- May-2020: Medtronic collaborated with UW following which the company has accelerated research into deep brain stimulation treatment for essential tremor, Parkinson’s disease, and other neurological disorders.
- Oct-2019: NeuroSigma came into partnership with Quick Care Pharmacy, a California-based specialty pharmacy. Following the partnership, the latter company was aimed to sell and distribute the former company’s Monarch eTNS System (Monarch) for the treatment of pediatric ADHD in the United States.
- Jun-2019: Neuronetics teamed up with Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business. Following the collaboration, Teijin sells NeuroStar Transcranial Magnetic Stimulation (TMS) in Japan.
- May-2019: Abbott came into partnership with the US National Institutes of Health (NIH). The partnership was aimed at developing unique insights and driving the application of neurostimulation therapies. The partnership is expected to provide the latter company’s neuroscience research initiative BRAIN access to Abbott’s neuromodulation technologies.
Acquisitions & Mergers
- Jan-2020: Medtronic took over Stimgenics, a startup company that has developed a novel spinal cord stimulation waveform. This acquisition enabled the company to expand its business in the SCS Market.
- Jun-2019: Boston Scientific acquired Vertiflex, a healthcare company. Through this acquisition, Vertiflex’s spinal cord stimulation and radiofrequency ablation have been added to Boston Scientific’s product portfolio.
Product Launches & Expansions
- Jan-2019: Boston Scientific introduced the Vercise Primary Cell (PC) and Vercise Gevia Deep Brain Stimulation (DBS) Systems. The systems feature the Vercise Cartesia Directional Lead. The systems have the technology that enables the physicians in controlling the range, shape, position, and direction of electrical stimulation to treat the symptoms of Parkinson’s disease (PD) through highly-personalized therapy.
- Jan-2019: Boston launched WaveWriter Spinal Cord Stimulator (SCS) System in Europe for providing the treatment of chronic pain to people in Europe.
- Mar-2020: Symmetry, LivaNova’s vagus nerve stimulation therapy for treatment-resistant depression, got CE Mark in Europe. Symmetry is a small implantable device designed for stimulating the vagus nerve to improve symptoms of depression and quality of life.
- Mar-2020: Neuronetics announced that its NeuroStar Advanced Therapy System has been approved by the FDA. This system is used for the treatment of bipolar depression. The system uses transcranial magnetic stimulation (TMS), a noninvasive form of neuromodulation, to stimulate areas of the brain that are underactive in depression.
- Mar-2020: NeuroPace received approval from FDA for MRI labeling. The approval was for its RNS systems that are programmed to help people living with seizures who don’t respond to medication. RNS system is the world’s only closed-loop brain-responsive neurostimulation system that helps to prevent seizures at their source. The system comprises of a neurostimulator, leads mounted at the seizure foci, a remote monitor that uploads data, as well as an RNS tablet and patient data system. The data systems help the physicians with viewing data over a secure website which can further be used for personalized therapies.
- Jan-2020: Medtronic secured a CE Mark for its Percept PC neurostimulator. It is the only deep brain stimulation (DBS) system launched in the EU with BrainSense technology, which senses and records brain signals while delivering DBS therapy to people with neurological disorders such as Parkinson’s disease.
- Jan-2020: Abbott Laboratories got approval from the US Food and Drug Administration (FDA) for its Infinity Deep Brain Stimulation (DBS) system. This system is expected to be used in the treatment of Parkinson’s disease. The system is expected to enable targeting a specific area of the brain known as the internal globus pallidus (GPi) for improving the symptoms of Parkinson’s disease not controlled by medication.
- Nov-2019: Nevro Corporation received approval from the FDA for the Senza Omnia Spinal Cord Stimulation (SCS) System. The Omnia system has been designed for delivering Nevro’s proprietary HF10 therapy in addition to all other available SCS frequencies.
- Spinal Cord Stimulators
- Deep Brain Stimulators
- Sacral Nerve Stimulators
- Vagus Nerve Stimulators
- Other Devices
- Pain Management
- Hearing Loss
- Urinary Incontinence
- Parkinson’s Disease
- Other Applications
- North America
- Abbott Laboratories
- Boston Scientific Corporation
- Nevro Corporation
- Medtronic PLC
- NeuroSigma, Inc.
- Integer Holdings Corporation
- LivaNova PLC
- NeuroPace, Inc.
- Neuronetics, Inc.
- Synapse BioMedical, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/24otpg
View source version on businesswire.com:https://www.businesswire.com/news/home/20200706005224/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: MEDICAL DEVICES HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 07/06/2020 06:24 AM/DISC: 07/06/2020 06:24 AM